CHICAGO, Illinois, September 15, 2026 — On Monday, the Food and Drug Administration hosted a public hearing about using psychedelic drugs in clinical practice moving forward. Clinicians, therapists, and researchers used the session to urge more clarity around safety standards as approval times shorten. The hearing comes as the White House issued a presidential executive order directing agencies to expedite access to these therapies.
An Accelerated Regulatory Timeline
In April of this year, President Trump signed an executive order directing the FDA to issue priority review vouchers for any psychedelic compound that shows evidence of breakthrough therapy in treatment. In addition, soon thereafter, the agency assigned psilocybin a priority review for treatment-resistant depression and methylone for PTSD. A final call on psilocybin could come as soon as late 2026, say officials.
The order also created a Right to Try pathway for serious mental illness and appropriated $50 million in psychedelic research funding. As part of the new mechanism, priority vouchers were already issued to Compass Pathways, Usona Institute, and Transcend Therapeutics. Those vouchers can compress review periods from about a year to maybe three or four months.
What Clinicians Are Asking For
Physicians who testified at the hearing called for uniform training before therapists can provide such treatment in a clinical setting. One of the most common complaints was the intensity of psychedelic sessions—lasting four to six hours—which can be hard to manage without trained supervision continually providing support. Concerned clinicians warned that mixed safety protocols may undermine public confidence in the treatments.
Released in July, the FDA’s finalized clinical trial guidance advises that two trained monitors watch each dosing session. It suggests formal driving studies and more stringent assessments of cardiac risks associated with specific psychedelic compounds. Officials at the agency said it will likely require a Risk Evaluation and Mitigation Strategy once any psychedelic drug is approved.
Screening Concerns for Vulnerable Patients
Psychiatrists have expressed concern about screening individuals with a personal or family history of certain conditions—including bipolar disorder, psychosis, and specific cardiac anatomy—who would need to be extremely cautious. They warn that psychedelic therapy is not appropriate for all patients with treatment-resistant depression or PTSD. Under federal law, everything other than ketamine and its derivative Spravato is still investigational.
The Drug Enforcement Administration is also considering rescheduling drugs on the Schedule I list that pass Phase 3 studies for serious mental health disorders more quickly. That review might facilitate access once treatments make it through FDA approval, but DEA rules would still be in effect until then. Clinicians indicate that managing the two agencies’ requests continues to be a major barrier for practices wanting to offer these therapies.
What Lies Ahead for Patients and Providers
In a separate effort, the Health Resources and Services Administration has sought public comment on approaches to education programs on psychedelic therapy delivery in outpatient clinical settings. That effort is intended for rural health centers that may not have the same specialized mental health infrastructure. The comment period on that proposal closed earlier this year, with guidance anticipated in the coming months.
In the meantime, patients who are wondering about psychedelic therapy should be aware that most compounds remain investigational and unapproved except in clinical trials. Physicians suggest talking to a knowledgeable psychiatrist about any potential interest in these therapies and treatments. With approval timelines moving faster than normal, providers say bright lines for federal safety standards will be critical to a safe rollout.
Insurance coverage is another issue that is still up in the air, as approval timelines continue to outpace payer policy changes. Mental health advocates are concerned that even approved treatments could still be prohibitively expensive for many patients. A few clinics are already experimenting with sliding-scale pricing to prepare for anticipated demand.
As clinical interest in the field has grown, training programs for licensed therapists are beginning to expand. Numerous universities have started offering continuing education courses on specific psychedelic-assisted therapy protocols. Experts suggest that if approvals unfold as expected, demand for trained providers will quickly outstrip supply.
Faster access has generally been welcomed by patient advocacy groups, but they continue to call for caution regarding safety oversight. They contend that velocity should not compromise careful oversight of trials involving declared sensitive or high-risk subjects. The continuing challenge facing regulators, clinicians, and patients in the coming months is how to balance the need for accelerated approval with proper safeguards.
